当前位置：
X-MOL 学术
›
Cancer Biol. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prognostic and clinicopathological significance of CXCL1 in cancers: a systematic review and meta-analysis.
Cancer Biology & Therapy ( IF 3.6 ) Pub Date : 2019-08-06 , DOI: 10.1080/15384047.2019.1647056 Zulei Zhang 1, 2 , Yuting Chen 1, 2 , Yaofei Jiang 2, 3, 4 , Yan Luo 4 , Hao Zhang 2 , Yakun Zhan 1
Cancer Biology & Therapy ( IF 3.6 ) Pub Date : 2019-08-06 , DOI: 10.1080/15384047.2019.1647056 Zulei Zhang 1, 2 , Yuting Chen 1, 2 , Yaofei Jiang 2, 3, 4 , Yan Luo 4 , Hao Zhang 2 , Yakun Zhan 1
Affiliation
Background The prognostic value of Chemokine (C-X-C motif) ligand 1 (CXCL1) in various types of cancer remains controversial. Here we aimed to evaluate the prognostic role of CXCL1 for cancer. Methods A comprehensively search of the PubMed, Embase, Web of Science, Wanfang and China National Knowledge Internet databases was conducted to retrieve eligible studies meeting the inclusion criteria. Overall survival (OS), progression-free survival (PFS) and various clinicopathological parameters were defined as endpoints. Stata SE12.0 software was used for quantitative meta-analysis. Results A total of 17 studies encompassing 2265 cancer patients were included. Our meta-analysis showed that patients with higher CXCL1 expression had significantly shorter OS, according to both multivariate (HR 1.51, 95% CI 1.19-1.83, P < .01) and univariate analysis (HR 2.08, 95% CI 1.62-2.54, P < .01). Furthermore, higher CXCL1 expression was significantly correlated with advanced TNM stage and lymph node metastasis (both P < .05). Conclusions High CXCL1 expression is a risk factor for cancer prognosis indicating a poor OS, and advanced TNM stage and lymph node metastasis, demonstrating that it may be a promising prognostic biomarker for different cancers.
更新日期：2019-11-01
京公网安备 11010802027423号